This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CMC Forum Summer 2017: Scientific Program
Share |


To view the final program, click here


Monday, July 17, 2017

Analytical Methodologies and Specifications 
Session Chairs: Bruce Thompson, Pfizer, Inc. and Andrew Weiskopf, Biogen 

Measurement Assurance for Regenerative Medicine Advanced Therapies
Anne Plant, National Institute of Standards and Technology (NIST)

Viral Vector Analytical Paradigms, Platforms, and Proposed Specifications
Eric Pastor, Sanofi

Development of Gene Edited Allogeneic CAR T-Cell Therapy
Julianne Smith, Cellectis

Accelerated CMC Development of Regenerative Medical Products
Yoshiaki Maruyama, Pharmaceuticals and Mecial Devices Agency (PMDA)


Comparability of Cell & Gene Therapy Products
Session Chairs: Paul Husak, Amgen Inc. and Stefanie Pluschkell, Pfizer, Inc. 

Cell Therapy Product Manufacturing Considerations
Mohammad Heidaran, CBER, FDA

GTx and AAV: Advancing Analytical Characterization to Improve Product Understanding, Control, and Comparability Exercises
Herb Runnels, Pfizer, Inc.

Manufacturing, Development, and Comparability Assessments of Cell and Gene Therapy Products for Marketing in Europe
Margarida Menezes-Ferreira, INFARMED

Comparability Studies for Autologous Cell Therapy Processes
Christopher Shen, Kite Pharma

Tuesday, July 18, 2017 

Cell & Gene Therapy Manufacturing Strategies 
Session Chairs: Sid Advant, Celgene Corporation and Shian-Jiun Shih, Tessa Therapeutics 

Regulation of Manufacturing Cell and Gene Therapy Products for Use in Phase 1 Clinical Trials
Adrian Gee, Baylor College of Medicine

Craig Beasley, Juno Therapeutics

Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective
Christopher Storbeck, Health Canada

Manufacturing and Commercialization of an Oncolytic Virus Product
Tia Bush, Amgen Inc.


Raw Materials Sourcing & Supply Chain 
Session Chairs: Kathleen Francissen, Genentech, a Member of the Roche Group, Steven Oh, CBER, FDA and Cindy Riggins, Novartis Pharmaceuticals Corporation 

Standards and Best Practices for Cell, Gene and Tissue-based Therapies 
Rebecca Potts, U.S. Pharmacopeia (USP)

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products
Angela Whatley, CBER, FDA

Integrated Supply Chain for Cell Therapy
Bryan Silvey, Kite Pharma

more Calendar

6/10/2019 » 6/12/2019
Cell & Gene Therapy Products 2019

7/15/2019 » 7/16/2019
CMC Strategy Forum North America Summer 2019

Membership Software Powered by YourMembership  ::  Legal